Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Priya U, Kumthekar"'
Autor:
Priya U. Kumthekar, Barbara Blouw, Perry Corkos, Seema Nagpal, Arushi Tripathy, David Piccioni, Michael Youssef
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionCNSide is a platform that detects and characterizes tumor cells in the cerebrospinal fluid (CSF) of patients with leptomeningeal disease (LMD). The platform was validated per College of American Pathologists (CAP) and Clinical Laboratorie
Externí odkaz:
https://doaj.org/article/a4602abf11c5492b932f0f10399332db
Autor:
Hinda Najem, Anantha Marisetty, Craig Horbinski, James Long, Jason T. Huse, Isabella C. Glitza Oliva, Sherise D. Ferguson, Priya U. Kumthekar, Derek A. Wainwright, Peiwen Chen, Maciej S. Lesniak, Jared K. Burks, Amy B. Heimberger
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Leptomeningeal disease (LMD) in melanoma patients is associated with significant neurological sequela and has a dismal outcome, with survival measured typically in weeks. Despite the therapeutic benefit of targeted therapies and immunotherapies for S
Externí odkaz:
https://doaj.org/article/16b483a25dff4d6a9860f968f5548dbe
Autor:
Priya U Kumthekar, Michael J Avram, Andrew B Lassman, Nancy U Lin, Eudocia Lee, Sean A Grimm, Margaret Schwartz, Kirsten L Bell Burdett, Rimas V Lukas, Karan Dixit, Isabella Perron, Hui Zhang, William J Gradishar, Elena I Pentsova, Suriya Jeyapalan, Morris D Groves, Michelle Melisko, Jeffrey J Raizer
Publikováno v:
Neuro-Oncology. 25:557-565
Background Patients with human epidermal growth factor receptor 2-positive (HER2-positive) cancers have a high incidence of central nervous system (CNS) spread, but unfortunately systemic trastuzumab which targets the HER2 receptor has little CNS pen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f77768f1b6a19e682c66e9d528a059e2
https://doi.org/10.1093/neuonc/noac195
https://doi.org/10.1093/neuonc/noac195
Autor:
Suneel D. Kamath, Priya U. Kumthekar
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
While the CNS has long been viewed as an immune-privileged environment, a paradigm shift in neuro-immunology has elevated the role of systemic immunotherapy for the treatment of metastatic disease. Increasing knowledge regarding the presence of a CNS
Externí odkaz:
https://doaj.org/article/e66513c49e7f428aa431e0eebe5f1e6c
Autor:
Priya U, Kumthekar, Michael J, Avram, Andrew B, Lassman, Nancy U, Lin, Eudocia, Lee, Sean A, Grimm, Margaret, Schwartz, Kirsten L, Bell Burdett, Rimas V, Lukas, Karan, Dixit, Isabella, Perron, Hui, Zhang, William J, Gradishar, Elena I, Pentsova, Suriya, Jeyapalan, Morris D, Groves, Michelle, Melisko, Jeffrey J, Raizer
Publikováno v:
Neuro-oncology.
Patients with human epidermal growth factor receptor 2-positive (HER2-positive) cancers have a high incidence of central nervous system (CNS) spread, but unfortunately systemic trastuzumab which targets the HER2 receptor has little CNS penetration. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::948572e4eefb2f070951c8b741c9d2be
https://pubmed.ncbi.nlm.nih.gov/35948282
https://pubmed.ncbi.nlm.nih.gov/35948282
Autor:
Priya U, Kumthekar, Bryan D, Macrie, Simran K, Singh, Gurvinder, Kaur, James P, Chandler, Samir V, Sejpal
Publikováno v:
American journal of cancer research. 4(5)
Glioblastoma Multiforme (GBM) is the most frequent primary malignant brain tumor in adults. It is an aggressive primary brain neoplasm, associated with a poor prognosis and median survival of less than 1 year. Approximately 50% of patients diagnosed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3c9c7efbb18cd950c4961f96f2bd39b1
https://pubmed.ncbi.nlm.nih.gov/25232486
https://pubmed.ncbi.nlm.nih.gov/25232486